<ul><li>Peptris Technologies licenses India’s first AI-discovered drug candidate, PEPR124 (RT001), to Revio Therapeutics, a rare genetic disorder.</li><li>Peptris Technologies has a pipeline of advanced preclinical assets in Rare Diseases, Alopecia, Inflammation, and Oncology.</li><li>PEPR124 (RT001) has shown promising results in preclinical studies and has a strong safety profile.</li><li>Revio Therapeutics will handle commercialisation of PEPR124 (RT001) in all markets except the BRICS countries.</li></ul>

Peptris Technologies Licenses India’s First AI-Discovered Drug Candidate to Revio Therapeutics

Discover more